



	Method	Specification	Result
Microbiological purity	Ph. Eur (current ed.) 5.1.4.		
<i>Total aerobic microbial count (TAMC)</i>	5.1.4.-1.	$\leq 10^2$ cfu/gram	$< 10^2$ cfu/gram
<i>Total yeast and moulds count (TYMC)</i>	5.1.4.-1.	$\leq 10^1$ cfu/gram	$< 10^1$ cfu/gram
<i>P. aeruginosa, S.aureus and Bile tolerant gram neg bacteria</i>	5.1.4.-1.	absent	conform
Absence of aflatoxins	Ph. Eur (current ed.) "Determination of aflatoxins B ₁ , B ₂ , G ₁ and G ₂ in herbal drugs" (2.8.18)	≤ 4 $\mu\text{g}/\text{kg}$	< 4.0 $\mu\text{g}/\text{kg}$
Absence of pesticides	Ph. Eur (current ed.) "Pesticide residues" (2.8.13)	\leq Limits Ph. Eur 2.8.13*	conform
Absence of heavy metal <i>lead</i> <i>mercury</i> <i>cadmium</i>	Ph. Eur (current ed.) "Heavy metals in herbal drugs and fatty oils" (monograph)	max. 20.0 ppm max. 0.5 ppm max. 0.5 ppm	< 5 ppm < 0.125 ppm < 0.125 ppm
Loss on drying	Ph. Eur (current ed.) "Loss on drying" meth. C (2.2.32)	≤ 10.0 %	7.6 %
Assay (HPLC)			
<i>tetrahydrocannabinol(THC)</i>	monograph	approx. 6.3 %	6.3 %
<i>cannabidiol (CBD)</i>	monograph	approx. 8 %	8.3 %
Related substances (HPLC)			
<i>cannabinol (CBN)</i>	monograph	< 1.0 %	< 0.1 %
Content of container	BMC-SWV 320	approx. 5 gram	± 5.14 gram
Expiry date			02 / 2022

*The following pesticides are not analysed: dithiocarbamates (expressed as CS₂), methoxychlor, paraoxon-methyl and tetradifon. The limit of detection is increased for fenpropathrin to 0.1 mg/kg and azinphos-ethyl to 1 mg/kg.

I hereby certify that the above information is authentic and accurate. This batch of product has been cultivated and manufactured, including packaging and quality control at the above mentioned sites in full compliance with the GAP requirements as published in the Dutch State Gazette (Staatscourant) as the annex to the Regulation of the Minister of Health, Welfare and Sport of 9 January 2003, GMT/BMC 2340685, and with the specifications as stated in this document. The batch processing, packaging and analysis records were reviewed and found to be in compliance with GAP and GMP.

The Hague, the Netherlands, 1 April 2021

Dr. M.J. van de Velde

Dr. M.J. van de Velde

head, Office of Medicinal Cannabis